All In Biotech

Drug Trial Radar · NCT07911553

A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5

A Phase III Study to Evaluate the Efficacy of Surovatamig Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Previously Untreated Large B-cell Lymphoma (Soundtrack D3)

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Dec 22, 2026

Primary completion

Sep 2, 2030

Study completion Sep 1, 2032

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) in participants aged 18 to \< 80 years of age with previously untreated large B-cell lymphoma (LBCL) with International Prognostic Index (IPI) score 2 to 5.

Conditions

  • Large B-cell Lymphoma

Interventions

  • SurovatamigDrug

    Fully human bispecific monoclonal immunoglobulins (Ig) G4 antibody

  • RituximabDrug

    Rituximab will be administered to participants as per SoC.

  • CyclophosphamideDrug

    Cyclophosphamide will be administered to participants as per SoC.

  • DoxorubicinDrug

    Doxorubicin will be administered to participants as per SoC.

  • VincristineDrug

    Vincristine will be administered to participants as per SoC.

  • PrednisoneDrug

    Prednisone (or equivalent) will be administered to participants as per SoC.

  • Polatuzumab vedotinDrug

    Polatuzumab vedotin will be administered to participants as per SoC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) as assessed by Blinded Independent Central Review (BICR)Time frame: Up to 10 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.